The p53-mediated cytotoxicity of photodynamic therapy of cancer: Recent advances

Toxicology and Applied Pharmacology

Volumn 232, Issue 3, 2008, Pages 487-497

  Zawacka Pankau, Joanna ^a,b   Krachulec, Justyna ^a   Grulkowski, Ireneusz ^c   Bielawski, Krzysztof P ^a   Selivanova, Galina ^b  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Aminolevulinic acid; Apoptosis; MDM2; MDM4; p53; Photodynamic therapy; Protoporphyrin IX

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID HEXYL ESTER; AMINOLEVULINIC ACID METHYL ESTER; ATX-S10NA(II); BENZVIX; DEFEROXAMINE MESYLATE; HEMATOPORPHYRIN; HEMATOPORPHYRIN DERIVATIVE; PHOTOFRIN; PHOTOGEM; PHOTOSAN; PORPHYRINOGEN; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; PROTEIN P63; PROTEIN P73; PROTOPORPHYRIN; RADACHLORIN; REACTIVE OXYGEN METABOLITE; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VERTEPORFIN;

APOPTOSIS; CANCER CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL DEATH; CYTOTOXICITY; GENE CONTROL; GENOTOXICITY; HUMAN; PHOTODYNAMIC THERAPY; PROTEIN STRUCTURE; REVIEW; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION;

EID: 53649106147     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2008.07.012     Document Type: Review

References (125)

1. Ahlskog J., Paganelli G., and Neri D. Vascular tumor targeting. Q. J. Nucl. Med. Mol. Imaging 50 4 (2006) 296-309
2. Alexander K., Yang H.S., and Hinds P.W. pRb inactivation in senescent cells leads to an E2F-dependent apoptosis requiring p73. Mol. Cancer Res. 1 (2003) 716-728
3. Allison R.R., Downie G.H., Cuenca R., Hu X., Childs C.J.H., and Sibata C.H. Photosensitizers in clinical PDT. Photodiagn. Photodyn. Ther. 1 (2004) 27-42
4. Almeida R.D., Manadas B.J., Carvalho A.P., and Duarte C.B. Intracellular signaling mechanisms in photodynamic therapy. Biochim. Biophys. Acta 1704 (2004) 59-86
5. Arkin M.R., and Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat. Rev. Drug Discov. 3 4 (2004) 301-317
6. Bayés M., and Rabasseda X. Gateways to clinical trials. Methods Find Exp. Clin. Pharmacol. 30 1 (2008) 67-99
7. Bednarz N., Zawacka-Pankau J., and Kowalska A. Protoporphyrin IX induces apoptosis in HeLa cells prior to photodynamic treatment. Pharmacol. Rep. 59 4 (2007) 474-479
8. Bell H.S., Dufes C., O'Prey J., Crighton D., Bergamaschi D., Lu X., Schätzlein A.G., Vousden K.H., and Ryan K.M. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo. J. Clin. Invest. 117 4 (2007) 1008-1018
9. Bénard J., Douc-Rasy S., and Ahomadegbe J.C. TP53 family members and human cancers. Hum. Mutat. 21 3 (2003) 182-191
10. Böttger V., Böttger A., Garcia-Echeverria C., Ramos Y.F., van der Eb A.J., Jochemsen A.G., and Lane D.P. Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18 1 (1999) 189-199
11. Bressler N.M. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol. 119 2 (2001) 198-207
12. Bronshtein I., Aulova S., Juzeniene A., Iani V., Ma L.W., Smith K.M., Malik Z., Moan J., and Ehrenberg B. In vitro and in vivo photosensitization by protoporphyrins possessing different lipophilicities and vertical localization in the membrane. Photochem. Photobiol. 82 5 (2006) 1319-1326
13. Buytaert E., Callewaert G., Hendrickx N., Scorrano L., Hartmann D., Missiaen L., Vandenheede J.R., Heirman I., Grooten J., and Agostinis P. Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. FASEB J. 20 6 (2006) 756-758
14. Buytaert E., Callewaert G., Vandenheede J.R., and Agostinis P. Deficiency in apoptotic effectors Bax and Bak reveals an autophagic cell death pathway initiated by photodamage to the endoplasmic reticulum. Autophagy 2 3 (2006) 238-240
15. Calzavara-Pinton P.G., Venturini M., Capezzera R., Sala R., and Zane C. Photodynamic therapy of interdigital mycoses of the feet with topical application of 5-aminolevulinic acid. Photodermatol. Photoimmunol. Photomed. 20 (2004) 144-147
16. Calzavara-Pinton P.G., Venturini M., and Sala R. A comprehensive overview of photodynamic therapy in the treatment of superficial fungal infections of the skin. J. Photochem. Photobiol. B. Biol. 78 (2005) 1-6
17. Carthy C.M., Granville D.J., Jiang H., Levy J.G., Rudin C.M., Thompson C.B., McManus B.M., and Hunt D.W. Early release of mitochondrial cytochrome c and expression of mitochondrial epitope 7A6 with a porphyrin-derived photosensitizer: Bcl-2 and Bcl-xL overexpression do not prevent early mitochondrial events but still depress caspase activity. Lab. Invest. 79 8 (1999) 953-965
18. Castano A.P., Demidova T.N., and Hamblin M.R. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagn. Photodyn. Ther. 1 (2004) 279-293
19. Chen L., Gilkes D.M., Pan Y., Lane W.S., and Chen J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 24 19 (2005) 3411-3422
20. Chène P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nat. Rev. Cancer 3 2 (2003) 102-109
21. Chène P., Fuchs J., Bohn J., García-Echeverría C., Furet P., and Fabbro D. A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. J. Mol. Biol. 299 1 (2000) 245-253
22. Chissov V.I., Sokolov V.V., Filonenko E.V., Menenkov V.D., Zharkova N.N., Kozlov D.N., Polivanov I.N., Prokhorov A.M., Pykhov R.L., and Smirnov V.V. Clinical fluorescent diagnosis of tumors using photosensitizer photogem. Khirurgiia (Mosk) 5 (1995) 37-41
23. Chiu S.M., Xue L.Y., Usuda J., Azizuddin K., and Oleinick N.L. Bax is essential for mitochondrion-mediated apoptosis but not for cell death caused by photodynamic therapy. Br. J. Cancer 89 8 (2003) 1590-1597
24. Chiu S.M., Xue L.Y., Azizuddin K., and Oleinick N.L. Photodynamic therapy-induced death of HCT 116 cells: apoptosis with or without Bax expression. Apoptosis 10 6 (2005) 1357-1368
25. Chu E.S.M., Wu R.W.K., Yow C.M.N., Wong T.K.S., and Chen J.Y. The cytotoxic and genotoxic potential of 5-aminolevulinic acid on lymphocytes: a comet assay study. Cancer Chemother. Pharmacol. 58 (2006) 408-414
26. Crescenzi E., Varriale L., Iovino M., Chiaviello A., Veneziani B.M., and Palumbo G. Photodynamic therapy with indocyanine green complements and enhances low-dose cisplatin cytotoxicity in MCF-7 breast cancer cells. Mol. Cancer Ther. 3 5 (2004) 537-544
27. Dahle J., Steen H.B., and Moan J. The mode of cell death induced by photodynamic treatment depends on cell density. Photochem. Photobiol. 70 (1999) 363-367
28. Eskes R., Desagher S., Antonsson B., and Martinou J.C. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell Biol. 20 3 (2000) 929-935
29. Ferrario A., von Tiehl K.F., Ruer N., Swarz M.A., Gill P.S., and Gomer C.J. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res. 60 (2000) 4066-4069
30. Fisher A.M., Danenberg K., Banerjee D., Bertino J.R., Danenberg P., and Gomer C.J. Increased photosensitivity in HL60 cells expressing wild-type p53. Photochem. Photobiol. 66 2 (1997) 265-270
31. Fisher A.M., Rucker N., Wong S., and Gomer C.J. Differential photosensitivity in wild-type and mutant p53 human colon carcinoma cell lines. J. Photochem. Photobiol. B. Biol. 42 2 (1998) 104-107
32. Fisher A.M., Ferrario A., Rucker N., Zhang S., and Gomer C.J. Photodynamic therapy sensitivity is not altered in human tumor cells after abrogation of p53 function. Cancer Res. 59 2 (1999) 331-335
33. Fotinos N., Campo M.A., Popowycz F., Gurny R., and Lange N. 5-Aminolevulinic acid derivatives in photomedicine: characteristics, application and perspectives. Photochem. Photobiol. 82 4 (2006) 994-1015
34. Francoz S., Froment P., Bogaerts S., De Clercq S., Maetens M., Doumont G., Bellefroid E., and Marine J.C. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc. Natl. Acad Sci. U.S.A. 103 9 (2006) 3232-3237
35. Fry D.C., and Vassilev L.T. Targeting protein-protein interactions for cancer therapy. J. Mol. Med. 83 12 (2005) 955-963
36. Gibbs S.L., Chen B., O'Hara J.A., Hoopes P.J., Hasan T., and Pogue B.W. Protoporphyrin IX level correlates with number of mitochondria, but increase in production correlates with tumor cell. Photochem. Photobiol. 82 5 (2006) 1334-1342
37. Graczyk A., and Sobczyńska J. Fotouczulacze stosowanme w metodzie fotodynamicznej PDT rozpoznawania i leczenia nowotworów (1999), Dom Wydawniczy Bellona, Warszawa, Poland 95-183
38. Granville D.J., Carthy M.C., Jiang H., Shore G.C., McManus B.M., and Hunt D.W.C. Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy. FEBS Lett. 437 (1998) 5-10
39. Granville D.J., Shaw J.R., Leong S., Carthy C.M., Margaron P., Hunt D.W., and McManus B.M. Release of cytochrome c, Bax migration, Bid cleavage, and activation of caspases 2, 3, 6, 7, 8, and 9 during endothelial cell apoptosis. Am. J. Pathol. 155 4 (1999) 1021-1025
40. Granville D.J., Carthy M.C., Jiang H., Levy B.M., McManus B.M., Matroule J.Y., Piette J., and Hunt D.W.C. Nuclear factorkappaB activation by the photochemotherapeutic agent verteporfin. Blood 95 (2000) 256-262
41. Green D.R., and Chipuk J.E. p53 and metabolism: inside the TIGAR. Cell 126 1 (2006) 30-32
42. Grinholc M., Kawiak A., Kurlenda J., Graczyk A., and Bielawski K.P. Photodynamic effect of protoporphyrin diarginate (PPArg(2)) on methicillin-resistant Staphylococcus aureus and human dermal fibroblasts. Acta Biochim. Pol. 55 1 (2008) 85-90
43. Hahn S.M., Fraker D.L., Mick R., Metz J., Busch T.M., Smith D., Zhu T., Rodriguez C., Dimofte A., Spitz F., Putt M., Rubin S.C., Menon C., Wang H.W., Shin D., Yodh A., and Glatstein E. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin. Cancer Res. 12 8 (2006) 2517-2525
44. Hainaut P., and Wiman C. 25 years of p53 research (2005), The Neaderlands, Springer
45. Haupt Y., Maya R., Kazaz A., and Oren M. Mdm2 promotes the rapid degradation of p53. Nature 387 6630 (1997) 296-299
46. Hayle A.K., Ward T.H., and Moore J.V. DNA damage and repair in Gorlin syndrome and normal fibroblasts after aminolevulinic acid photodynamic therapy: a comet assay study. Photochem. Photobiol. 78 (2003) 337-341
47. Hilf R. Mitochondria are targets of photodynamic therapy. J. Bioenerg. Biomembr. 39 1 (2007) 85-89
48. Honda R., Tanaka H., and Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420 1 (1997) 25-27
49. Horn M., Wolf P., Wulf H.C., Warloe T., Fritsch C., Rhodes L.E., Kaufmann R., De Rie M., Legat F.J., Stender I.M., Solér A.M., Wennberg A.M., Wong G.A., and Larkö O. Topical methyl aminolevulinate therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. Brit. J. Dermatol. 149 (2003) 1242-1249
50. Huang Z. A review of progress in clinical photodynamic therapy. Technol. Cancer Res. Treat. 4 3 (2005) 283-293
51. Irwin M.S., Kondo K., Marin M.C., Cheng L.S., Hahn W.C., and Kaelin Jr. W.G. Chemosensitivity linked to p73 function. Cancer Cell 3 4 (2003) 403-410
52. Issaeva N., Bozko P., Enge M., Protopopova M., Verhoef L.G., Masucci M., Pramanik A., and Selivanova G. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat. Med. 10 12 (2004) 1321-1328
53. Jeffers E.W., McCullough J.L., Weinstein G.D., Kaplan R., Glazer S.D., and Taylor J.R. Photodynamic therapy of actinic keratosis with topical aminolevulinic acid hydrochloride and fluorescent blue light. J. Am. Acad. Dermatol. 45 (2001) 96-104
54. Jin S., and Levine A.J. The p53 functional circuit. J. Cell Sci. 114 (2001) 4139-4140
55. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X., Ferrara P., McKeon F., and Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
56. Kato H. Photodynamic therapy for lung cancer - a review of 19 years' experience. J. Photochem. Photobiol. B. 42 (1998) 96-99
57. Kelty C.J., Ackroyd R., Brown N.J., Brown S.B., and Reed M.W.R. Comparison of high-vs low-dose 5-aminolevulinic acid for photodynamic therapy of Barret's esophagus. Surg. Endosc. 18 (2004) 452-458
58. Kennedy J.C., Pottier R.H., and Pross D.C. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J. Photochem. Photobiol. B. 1-2 (1990) 143-148
59. Kessel D. Photodynamic therapy: from the beginning. Photodiag. Photodyn. Therapy 1 1 (2004) 3-7
60. Kessel D., and Luo Y. Mitochondrial photodamage and PDT-induced apoptosis. J. Photochem. Photobiol. B. Biol. 42 (1998) 89-95
61. Kessel D., Vicente M.G., and Reiners J.J. Initiation of apoptosis and autophagy by photodynamic therapy. Autophagy 2 4 (2006) 289-290
62. Klein C., and Vassilev L.T. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 91 8 (2004) 1415-1419
63. Koningsberger J.C., Rademakers L.H.I.M., van Hatturn J., de la Faille H.B., Wiegman L.J.J.M., Italiaander E., van Berge Henegouwen G.I., and Marx J.J.M. Exogenous protoporphyrin inhibits Hep G2 cell proliferation, increases the intracellular hydrogen peroxide concentration and causes ultrastructural alterations. J. Hepatol. 22 (1995) 57-65
64. Kralova J., Synytsya A., Pouckova P., Koc M., Dvorak M., and Kral V. Novel porphyrin conjugates with a potent photodynamic antitumor effect: differential efficacy of mono- and bis-[beta]-cyclodextrin derivatives in vitro and in vivo. Photochem. Photobiol. 2 (2006) 432-439
65. Kramer B., and Plaetzer K. ALA and its clinical impact, from bench to bedside. Photochem. Photobiol. Sci. 7 (2008) 283-289
66. Kubbutat M.H., Jones S.N., and Vousden K.H. Regulation of p53 stability by Mdm2. Nature 387 6630 (1997) 299-303
67. Kwitniewski M., Kunikowska D., Dera-Tomaszewska B., Tokarska-Pietrzak E., Dziadziuszko H., Graczyk A., and Glosnicka R. Influence of diamino acid derivatives of protoporphyrin IX on mouse immunological system: preliminary results. J. Photochem. Photobiol. B. 81 3 (2005) 129-135
68. Landers J.E., Cassel S.L., and George D.L. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res. 57 16 (1997) 3562-3568
69. Lee H.B., Ho A.S., and Teo S.H. p53 status does not affect photodynamic cell killing induced by hypericin. Cancer Chemother. Pharmacol. 58 1 (2006) 91-98
70. Lee J.S., Shukla A., Schneider J., Swanson S.K., Washburn M.P., Florens L., Bhaumik S.R., and Shilatifard A. Histone crosstalk between H2B monoubiquitination and H3 methylation mediated by COMPASS. Cell 131 (2007) 1084-1096
71. Levine A.J., Hu W., Feng Z., and Gil G. Reconstructing signal transduction pathways: challenges and opportunities. Ann. N. Y. Acad. Sci. 1115 (2007) 32-50
72. Li Y., and Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?. Oncogene 26 15 (2007) 2220-2225
73. Lim D.S., Bae S.M., Kwak S.Y., Park E.K., Kim J.K., Han S.J., Oh C.H., Lee C.H., Lee W.Y., and Ahn W.S. Adenovirus-mediated p53 treatment enhances photodynamic antitumor response. Hum. Gene Ther. 17 3 (2006) 347-352
74. Love D.E.B.W.G. Photodynamic therapy comes of age. I Drugs 3 (2000) 1487-1508
75. Luo Y., and Kessel D. Initiation of apoptosis versus necrosis by photodynamic therapy with chloroaluminum phthalocyanine. Photochem. Photobiol. 66 (1997) 479-483
76. Ma L.W., Bagdonas S., and Moan J. The photosensitizing effect of the photoproduct of protoporphyrin IX. J. Photochem. Photobiol. B. Biol. 60 (2001) 10-113
77. Maier A., Tomaselli F., Matzi V., Woltsche M., Anegg U., Fell B., Rehak P., Pinter H., and Smolle-Jüttner F.M. Comparison of 5-aminolaevulinic acid and porphyrin photosensitization for photodynamic therapy of malignant bronchial stenosis: a clinical pilot study. Lasers Surg. Med. 30 1 (2002) 12-17
78. Malik Z., and Lugaci H. Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. Br. J. Cancer 56 5 (1987) 589-595
79. Manivasager V., Heng P.W.S., Hao J., Zheng W., Soo K.C., and Olivio M. A study of 5-aminolevulinic acid and its methyl ester used in in vitro and in vivo systems of human bladder cancer. Int. J. Oncol. 22 (2003) 313-318
80. Marine J.C., and Jochemsen A.G. Mdmx as an essential regulator of p53 activity. Biochem. Biophys. Res. Commun. 331 3 (2005) 750-760
81. Marine J.C., Francoz S., Maetens M., Wahl G., Toledo F., and Lozano G. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 13 6 (2006) 927-934
82. Marine J.C., Dyer M.A., and Jochemsen A.G. MDMX: from bench to bedside. J. Cell Sci. 120 (2007) 371-378
83. McBride G. Studies expand potential uses of photodynamic therapy. J. Natl. Cancer Inst. 94 (2002) 1740-1742
84. Minsky N., and Oren M. The RING domain of Mdm2 mediates histone ubiquitylation and transcriptional repression. Mol. Cell 16 4 (2004) 631-639
85. Mitsunaga M., Tsubota A., Nariai K., Namiki Y., Sumi M., Yoshikawa T., and Fujise K. Early apoptosis and cell death induced by ATX-S10Na (II)-mediated photodynamic therapy are Bax- and p53-dependent in human colon cancer cells. World J. Gastroenterol. 13 5 (2007) 692-698
86. Moan J., and Peng Q. An outline of the hundred-year history of PDT. Anticancer Res. 23 5 (2007) 3591-3600
87. Moll U.M., Wolff S., Speidel D., and Deppert W. Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 17 6 (2007) 631-636
88. Momand J., Jung D., Wilczynski S., and Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 26 15 (1998) 3453-3459
89. Moor A.C. Signaling pathways in cell death and survival after photodynamic therapy. J. Photochem. Photobiol. B. Biol. 57 1 (2000) 13
90. Mori M., Kuroda T., Obana A., Sakata I., Hirano T., Nakajima S., Hikida M., and Kumagai T. In vitro plasma protein binding and cellular uptake of ATX-S10(Na), a hydrophilic chlorine photosensitizer. Jpn. J. Cancer Res. 91 8 (2000) 845-852
91. Okorokov A.L., Sherman M.B., Plisson C., Grinkevich V., Sigmundsson K., Selivanova G., Milner J., and Orlova E.V. The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity. EMBO J. 25 21 (2006) 5191-5200
92. Oleinick N.L., Morris R.L., and Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem. Photobiol. Sci. 1 1 (2002) 1-21
93. Patton J.T., Mayo L.D., Singhi A.D., Gudkov A.V., Stark G.R., and Jackson M.W. Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res. 66 6 (2006) 3169-3176
94. Peng Q., Warloe T., Berg K., Moan J., Kongshaug M., Giercksky K.E., and Nesland J.M. 5-Aminolevulinic acid-based photodynamic therapy. Cancer 79 (1997) 2282-2308
95. Pervaiz S. Reactive oxygen-dependent production of novel photochemotherapeutic agents. The FASEB J. 15 3 (2001) 612-617
96. PhotoCure ASA, 2002. High clinical acceptance of metvixÒ pdt., Second Quarter Report.
97. Piette J., Volanti C., Vantieghem A., Matroule J.Y., Habraken Y., and Agostinis P. Cell death and growth arrest in response to photodynamic therapy with membranebound photosensitizers. Biochem. Pharmacol. 66 (2003) 1651-1659
98. Podbielska H., Sieroń A., and Stre{ogonek}k W. Diagnostyka i terapia fotodynamiczna (2004), Wydawnictwo Medyczne Urban & Partner, Wrocław, Poland
99. Popowicz G.M., Czarna A., Rottweiler U., Sszwagierczak A., Krajewski M., Weber L., and Holak T.A. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 6 19 (2007)
100. Saczko J., Mazurkiewicz M., Chwiłkowska A., Kulbacka J., Kramer G., Ługowski M., Snietura M., and Banaś T. Intracellular distribution of photofrin in malignant and normal endothelial cell lines. Folia. Biol. (Praha) 53 1 (2007) 7-12
101. Selivanova G. Mutant p53: the loaded gun. Curr. Opin. Investig. Drugs. 2 8 (2001) 1136-1141
102. Sharp D.A., Kratowicz S.A., Sank M.J., and George D.L. Stabilization of the MDM2 oncoprotein by interaction with the structurally related MDMX protein. J. Biol. Chem. 274 53 (1999) 38189-38196
103. Shen X.Y., Zacal N., Singh G., and Rainbow A.J. Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells. Photochem. Photobiol. 81 2 (2005) 306-313
104. Shilatifard A. Molecular implementation and physiological roles for histone H3 lysine 4 (H3K4) methylation. Curr. Opin. Cell Biol. 20 (2008) 341-348
105. Shimizu S., Narita M., and Tsujimoto Y. Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature 399 6735 (1999) 483-487 Erratum in: Nature 2000; 407(6805): 767
106. Shvarts A., Steegenga W.T., Riteco N., van Laar T., Dekker P., Bazuine M., van Ham R.C., van der Houven, van Oordt W., Hateboer G., van der Eb A.J., and Jochemsen A.G. MDMX: a novel p53-binding protein with some functional properties of MDM2. EMBO J. 15 19 (1996) 5349-5357
107. Silva J.N., Filipe P., and Morliere P. Photodynamic therapies: principles and present medical applications. Biomed. Mater Eng. 16 Suppl. 4 (2006) 147-154
108. Stringer M., and Moghissi K. Photodiagnosis and fluorescence imaging in clinical practice. Photodiagn. Photodyn. Ther. 1 (2004) 9-12
109. Szeimies R.M., Karrer S., Radakovic-Fijan S., Tanew A., Calzavara-Pinton P.G., Zane C., Sidoroff A., Hempel M., Ulrich J., Proebstle T., Meffert H., Mulder M., Salomon D., Dittmar H.C., Bauer J.W., Kernland K., and Braathen L. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective randomized study. J. Am. Acad. Dermatol. 47 (2002) 258-262
110. Tano Y. Ophthalmic PDT Study Group. Guidelines for PDT in Japan. Ophthalmology 115 3 (2008) 585 e6
111. Toledo F., and Wahl G.M. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 6 12 (2006) 909-923
112. Toledo F., and Wahl G.M. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int. J. Biochem. Cell Biol. 39 7-8 (2007) 1476-1482
113. Triesscheijn M., Baas P., Schellens J.H.M., and Stewart F.A. Photodynamic therapy in oncology. Oncologist 11 9 (2006) 1034-1044
114. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., and Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303 5659 (2004) 844-848
115. VIP report no. 1. Verteporfin In Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial-2001. Ophthalmology 108 5 (2001) 841-852
116. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 8 (2002) 594-604
117. Wang P., Reed M., Wang Y., Mayr G., Stenger J.E., Anderson M.E., Schwedes J.F., and Tegtmeyer P. p53 domains: structure, oligomerization, and transformation. Mol. Cell Biol. 14 (1994) 5182-5191
118. Woods J.A., Traynor N.J., Brancaleon L., and Moseley H. The effect of photofrin on DNA strand breaks and base oxidation in HaCaT keratinocytes: a comet assay study. Photochem. Photobiol. 79 (2004) 105-113
119. Wyld L., Reed M.W.R., and Brown N.J. Differential cell death response to photodynamic therapy is dependent on dose and cell type. Br. J. Cancer 84 (2001) 1384-1386
120. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F., and Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404 (2000) 99-103
121. Yang Y., Ludwig R.L., Jensen J.P., Pierre S.A., Medaglia M.V., Davydov I.V., Safiran Y.J., Oberoi P., Kenten J.H., Phillips A.C., Weissman A.M., and Vousden K.H. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7 6 (2005) 547-559
122. Zawacka-Pankau J., Issaeva N., Hossain S., Pramanik A., Selivanova G., and Podhajska A.J. Protoporphyrin IX interacts with wild-type p53 protein in vitro and induces cell death of human colon cancer cells in a p53-dependent and -independent manner. J. Biol. Chem. 282 4 (2007) 2466-2472
123. Zawacka-Pankau J., Kowalska A., Issaeva N., Burcza A., Kwiek P., Bednarz N., Pramanik A., Banecki B., and Podhajska A.J. Tumor suppressor Fhit protein interacts with protoporphyrin IX in vitro and enhances the response of HeLa cells to photodynamic therapy. J. Photochem. Photobiol. B. 86 1 (2007) 35-42
124. Zeng X., Chen L., Jost C.A., Maya R., Keller D., Wang X., Kaelin Jr. W.G., Oren M., Chen J., and Lu H. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell Biol. 19 5 (1999) 3257-3266
125. Zhou X., Chen B., Hoopes P.J., Hasan T., and Pogue B.W. Tumor vascular area correlates with photosensitizer uptake: analysis of verteporfin microvascular delivery in the dunning rat prostate tumor. Photochem. Photobiol. 82 5 (2006) 1348-1357